Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Dialogue to Be Held Once or Twice a Year: EAD Director
February 12, 2007
- ON THE MOVE
February 12, 2007
- 1st Gov't-Private Sector Dialogue Held
February 12, 2007
- BUSINESS NEWS IN BRIEF
February 12, 2007
- NEW PRODUCTS
February 12, 2007
- AstraZeneca to Cut 3,000 Jobs Worldwide
February 12, 2007
- Tanabe Seiyaku, Mitsubishi Pharma Corporation to Merge Oct. 1
February 12, 2007
- Tohoku Univ. Researchers Develop New Endoscopic Laser Treatment System
February 12, 2007
- Olympus Applies for Swallowable Imaging Capsule
February 12, 2007
- PREMINENT Opens Door to Combination Drugs
February 12, 2007
- Olympus Launches World's First AFT Videoscopes
February 12, 2007
- GENERIC NEWS IN BRIEF
February 12, 2007
- Original Products Holding Their Own in Competition with Generics
February 12, 2007
- R&D NEWS IN BRIEF
February 12, 2007
- Molecular Imaging Research Symposium 2007
February 12, 2007
- Mochida Aims to Become Specialty Pharma Focused in 4 Fields
February 5, 2007
- REGULATORY NEWS IN BRIEF
February 5, 2007
- Course and Strategy for Japanese Economy Approved by Cabinet
February 5, 2007
- Pfizer Embarks on Major Restructuring
February 5, 2007
- COMMENTARY From Convoy System to Competition
February 5, 2007
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…